Alivus Life Sciences Ltd (ALIVUS) Q1FY26 Concall Summary - Jun-2025 Qtr
Performance Overview
- Glenmark Life Sciences reported revenue of 602 crores, a 2.2% YoY growth driven by the non-GPL business.
- Non-GPL business grew 14.5% YoY and 4.1% QoQ, fueled by successful new product launches.
- GPL business declined 20.2% YoY due to inventory rationalization, impacting the generic API business.
- Gross margin increased to 55.1%, up 400 basis points YoY due to lower input costs and improved operational efficiency.
- Dahej facility received EIR from US FDA with NAI classification, while Ankleshwar facility received its EIR earlier in the year.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.